Olmefast
Generic Name
Olmesartan Medoxomil
Manufacturer
Beximco Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmefast 20 mg tablet | ৳ 8.00 | ৳ 80.00 |
Description
Overview of the medicine
Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It helps to relax blood vessels, allowing blood to flow more easily.
Uses & Indications
Dosage
Adults
Initial dose is 20 mg once daily. May be increased to 40 mg once daily if needed. Maximum daily dose is 40 mg.
Elderly
No initial dosage adjustment is usually required for elderly patients, unless they have severe renal impairment.
Renal_impairment
For patients with moderate to severe renal impairment (creatinine clearance <40 mL/min), a lower starting dose (e.g., 10 mg once daily) may be considered, and careful monitoring is recommended.
How to Take
Olmefast-20-mg-tablet should be taken orally, once daily, with or without food. It is recommended to take it at about the same time each day.
Mechanism of Action
Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, reducing vasoconstriction and aldosterone-secreting effects. This leads to a decrease in blood pressure.
Pharmacokinetics
Onset
Blood pressure reduction begins within 2 weeks, with full effect usually achieved within 8 weeks.
Excretion
Approximately 35-50% excreted via urine and 50-65% via bile/feces.
Half life
Approximately 13 hours.
Absorption
Rapidly absorbed from the gastrointestinal tract, with absolute bioavailability of approximately 26%. Peak plasma concentrations are reached within 1-2 hours.
Metabolism
Olmesartan medoxomil is rapidly and completely converted to olmesartan during absorption. Olmesartan is not significantly metabolized by the cytochrome P450 system.
Side Effects
Contraindications
- •Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- •Pregnancy (second and third trimesters) due to fetal toxicity.
- •Concomitant use with aliskiren in patients with diabetes or renal impairment.
Drug Interactions
NSAIDs
May reduce the antihypertensive effect of olmesartan. Co-administration may worsen renal function in dehydrated patients or those with impaired renal function.
Lithium
Increased serum lithium concentrations and lithium toxicity. Monitor lithium levels.
Aliskiren
Contraindicated in patients with diabetes or renal impairment (GFR <60 mL/min/1.73 m2).
Diuretics and other Antihypertensives
May enhance the hypotensive effect.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension and possibly tachycardia; bradycardia could occur from parasympathetic stimulation. Treatment is symptomatic and supportive. Administer activated charcoal shortly after ingestion.
Pregnancy & Lactation
Contraindicated in the second and third trimesters of pregnancy due to risk of fetal injury or death. Not recommended during breastfeeding as it is unknown if olmesartan is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 3 years from manufacturing date.
Availability
Available in pharmacies and hospitals
Approval Status
FDA Approved, DGDA Approved
Patent Status
Off-patent in many regions
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
